Affiliation:
1. Department of Rheumatology, Xiangya Hospital, Central South University
2. Department of Rheumatology, Peking Union Medical College Hospital
Abstract
Abstract
Background: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of systemic sclerosis (SSc) -related death. In this study, we aimed to identify biomarkers for detecting SSc pulmonary complications that are mild and in the early stages to improve the prognosis.
Methods: We screened for serum biomarkers using a proteomic antibody microarray that simultaneously assessed 1,000 proteins. Differentially expressed proteins were further verified using ELISA. Finally, we performed a correlation analysis using clinical data.
Results: We identified 125 differentially expressed proteins, of which calcitonin, sclerostin (SOST), CD40, and fibronectin were selected for further verification. Serum calcitonin and SOST levels were significantly elevated in all SSc pulmonary complication subgroups, whereas serum calcitonin levels were higher in the SSc with PAH subgroup than in the SSc without PAH and ILD subgroup. Serum SOST levels were possibly associated with the presence of ILD and positively related to the presence of cardiac and gastrointestinal involvement. Serum CD40 and calcitonin levels appeared to be positively related to the presence of renal involvement, and serum calcitonin was also positively related to the presence of gastrointestinal involvement.
Conclusions: This study indicated that serum calcitonin and SOST levels may be promising biomarkers for SSc-related PAH and ILD, respectively. Further research is needed to verify this result and understand the underlying mechanisms.
Publisher
Research Square Platform LLC
Reference51 articles.
1. The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis;Mouawad JE;International journal of molecular sciences,2023
2. Independent Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis;Barkhane Z;Cureus,2023
3. Mapping and predicting mortality from systemic sclerosis;Elhai M;Annals of the rheumatic diseases,2017
4. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease;Rahaghi FF;Respiratory research,2023
5. Systemic Sclerosis and Pulmonary Disease;Ngo K;Advances in experimental medicine and biology,2021